EX-99.1 2 ea024213601ex99-1_synergy.htm PRESS RELEASE, DATED MAY 15, 2025

Exhibit 99.1

 

 

Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

 

WESTBROOK, Maine, May 15, 2025 – Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025.

 

“We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability,” said Jack Ross, CEO of Synergy. “Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management.”

 

“We continue to make meaningful progress toward our 2025 priorities, including preparing for international expansion into three new markets later this year for our FOCUSfactor brand and Ready-To-Drink beverages, and expanding our Flat Tummy product line in response to rising interest in GLP-1 support. We also successfully entered into term sheets to refinance our debt that we expect to close as expeditiously as possible, which is expected to accelerate free cash flow in the business in the near term and extend our debt maturity date into 2029. This will provide us the added flexibility to pursue our long-term strategic goals and accelerate our 2025 growth initiatives. With continued momentum and the expected refinancing, Synergy has a clear path forward. We remain confident in our ability to drive sustainable growth and shareholder value. We are truly excited about our ability to accelerate our growth initiatives in the coming quarters.”

 

First Quarter 2025 Financial Summary vs. Same Year-Ago Period

 

●Revenue of $8.2 million vs. $9.4 million.
●Gross margin of 75.4% vs. 72.0%.
●Income from operations of $1.9 million vs. $1.8 million.
●Net income of $876.3 thousand vs. $580.5 thousand.
●Earnings per share of $0.10 vs. $0.08.
●EBITDA, a non-GAAP financial measure, was $1.98 million vs. $1.85 million.

 

Recent Business Highlights

 

●Synergy entered and continued debt refinancing negotiations during and after the first quarter, aiming to extend the maturity to 2029.
●Synergy has established a wholly owned subsidiary in Mexico and is actively working to onboard several key suppliers and retailers in the region.
●Synergy signed a new long-term supplier agreement for FOCUSfactor products, effective April 2025, which is expected to deliver significant cost savings.
●During the first quarter, the Company reduced outstanding liabilities by $1.7 million.

 

First Quarter 2025 Financial Results

 

Revenue in the first quarter of 2025 was $8.2 million, down 13% compared to $9.4 million in the first quarter of 2024. The decrease was driven by a new product sell-in to one customer in 2024, that did not repeat in 2025.

 

 

 

Gross margin in the first quarter of 2025 was 75.4% compared to 72.0% in the first quarter of 2024. The increase was largely driven by a favorable shift in product mix.

 

Operating expenses in the first quarter of 2025 were $4.2 million, down 15% compared to $5.0 million in the first quarter of 2024. The improvement was driven by management of operating costs and the decrease in net revenue.

 

Income from operations for the first quarter of 2025 was $1.9 million, up 8% compared to $1.8 million in the first quarter of 2024. The increase in operating income was due to a decrease in operating expenses.

 

Net income in the first quarter of 2025 was $876.3 thousand, up 51% compared to net income of $580.5 thousand in the first quarter of 2024.

 

EBITDA (a non-GAAP financial measure) in the first quarter of 2025 was $1.98 million, up 7% compared to $1.85 million in the first quarter of 2024. The increase was primarily due to lower SG&A expenses.

 

Balance Sheet and Cash Flow

 

As of March 31, 2025, Synergy had approximately $177.9 thousand in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024. As of March 31, 2025, Synergy had $31.3 million in total liabilities, compared to $33.0 million in total liabilities as of December 31, 2024, an improvement of $1.7 million.

 

As of March 31, 2025, Synergy had $2.3 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

 

Cash used in operating activities for the three months ended March 31, 2025 was $822.8 thousand compared to cash used in operating activities of $858 thousand for the three months ended March 31, 2024.

 

EBITDA

 

Along with this information, to assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors’ overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

 

The following table reconciles net income to EBITDA (in millions of US dollars):

 

   3 Months ended March 31 
   2025   2024 
Net income for the period  $0.88   $0.58 
Adjusted for:          
Interest expense, net   1.08    1.11 
Amortization of intangible assets   0.03    0.03 
Taxes expense (benefit)   (0.01)   0.13 
EBITDA  $1.98   $1.85 

 

2

 

Conference Call

 

In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on May 15, 2025 with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

 

About Synergy CHC Corp.

 

Synergy CHC Corp. is a provider of consumer health care and lifestyle products. Synergy’s current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their weight management goals.

 

Forward Looking Statements

 

Certain statements contained in this press release constitute “forward-looking statements,” including statements regarding expansion and growth initiatives, refinancing of our indebtedness and our free cash flow. These forward-looking statements represent Synergy’s expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy’s registration statement on Form S-1, as amended, many of which are outside of Synergy’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

 

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy’s filings could cause its actual results to differ materially from those contained in any forward-looking statement.

 

Investor Relations

 

Gateway Group

Cody Slach

949.574.3860

[email protected]

 

3

 

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

 

   March 31,
2025		   December 31,
2024		 
   (unaudited)     
Assets        
Current Assets        
Cash and cash equivalents  $177,882   $        687,920 
Restricted cash   100,000    100,000 
Accounts receivable, net   4,380,518    5,321,037 
Other receivables   1,855,000    1,999,637 
Loan receivable (related party)   4,375,892    4,375,059 
Prepaid expenses (including related party amount of $508,879 and $312,966, respectively)   2,170,263    1,859,563 
Inventory, net   2,346,487    1,716,552 
Total Current Assets   15,406,042    16,059,768 
           
Intangible assets, net   250,000    283,333 
           
Total Assets  $15,656,042   $16,343,101 
           
Liabilities and Stockholders’ Deficit          
Current Liabilities:          
Accounts payable and accrued liabilities (including related party payable of $217,956 and $88,644, respectively)  $3,098,590   $5,191,868 
Income taxes payable   77,564    242,977 
Contract liabilities   36    24,252 
Short term loans payable, net of debt discount   4,754,555    7,725,272 
Current portion of long-term notes payable, net of debt discount and debt issuance cost, related party   135,000    4,000,000 
Total Current Liabilities   8,065,745    17,184,369 
           
Long-term Liabilities:          
Notes payable, net of debt discount, related parties   12,333,053    8,333,053 
Notes payable   10,896,610    7,457,022 
Total long-term liabilities   23,229,663    15,790,075 
Total Liabilities   31,295,408    32,974,444 
           
Commitments and contingencies          
           
Stockholders’ Deficit:          
Common stock, $0.00001 par value; 300,000,000 shares authorized; 8,752,178 and 8,721,818, shares issued, respectively; 8,572,105 and 8,541,745 outstanding, respectively   88    87 
Additional paid in capital   27,761,307    27,643,660 
Accumulated other comprehensive loss   (49,712)   (47,777)
Accumulated deficit   (43,223,549)   (44,099,813)
Less: Treasury stock (180,073 shares) at cost   (127,500)   (127,500)
Total stockholders’ deficit   (15,639,366)   (16,631,343)
Total Liabilities and Stockholders’ Deficit  $15,656,042   $16,343,101 

 

4

 

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Income and Comprehensive Income

 

   For the three months ended   For the three
months ended		 
   March 31,
2025		   March 31,
2024		 
Revenue        
Product Sales   6,670,534   $9,411,863 
License Revenue   1,500,000    - 
Total Revenue   8,170,534    9,411,863 
           
Cost of Sales   2,006,513    2,637,139 
           
Gross Profit   6,164,021    6,774,724 
           
Operating expenses          
Selling and marketing   2,876,271    3,584,677 
General and administrative   1,306,714    1,348,385 
Depreciation and amortization   33,333    33,333 
Total operating expenses   4,216,318    4,966,395 
           
Income from operations   1,947,703    1,808,329 
           
Other (income) expenses          
Interest income   (13,882)   (387)
Interest expense   1,095,369    1,109,980 
Remeasurement loss (gain) on translation of foreign subsidiary   1,412    (8,983)
           
Total other expenses   1,082,899    1,100,610 
           
Net income before income taxes   864,804    707,719 
Income tax benefit (expense)   11,460    (127,189)
           
Net income after tax  $876,264   $580,530 
           
Net income per share – basic  $0.10   $0.08 
Net income per share – diluted  $0.10   $0.08 
           
Weighted average common shares outstanding          
Basic   8,560,636    7,373,745 
Diluted   8,577,620    7,373,745 
Comprehensive income:          
Net income  $876,264   $580,530 
Foreign currency translation adjustment   (1,935)   131,637 
Comprehensive income  $874,329   $712,167 

 

5

 

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Cash Flows 

 

   For the three
months ended		   For the three months ended 
   March 31,
2025		   March 31,
2024		 
Cash Flows from Operating Activities        
Net income  $876,264   $580,530 
Adjustments to reconcile net income to net cash used in operating activities:          
Amortization of debt discount and debt issuance cost   406,841    - 
Depreciation and amortization   33,333    33,334 
Foreign currency transaction loss (gain)   (3,137)   11,178 
Remeasurement gain on translation of foreign subsidiary   (1,412)   (8,983)
Non cash implied interest   -    7,199 
Changes in operating assets and liabilities:          
Accounts receivable   940,519    (318,330)
Other receivables   144,637    - 
Loan receivable, related party   (833)   25,162 
Inventory   (629,935)   1,016,455 
Prepaid expenses   (114,787)   (202,888)
Prepaid expense, related party   (195,913)   (165,687)
Income taxes payable   (165,413)   (20,315)
Contract liabilities   (24,216)   12,932 
Accounts payable and accrued liabilities   (2,218,041)   (1,808,989)
Accounts payable, related party   129,312    (19,640)
Net cash used in operating activities   (822,781)   (858,042)
           
Cash Flows from Investing Activities   -    - 
           
Cash Flows from Financing Activities          
Advances from related party   135,000    1,400,000 
Repayment of notes payable, related party   -    (84,500)
Proceeds from notes payable   1,496,250    125,000 
Repayment of notes payable   (1,316,572)   (435,880)
Net cash provided by financing activities   314,678    1,004,620 
           
Effect of exchange rate on cash, cash equivalents and restricted cash   (1,935)   131,637 
Net decrease in cash, cash equivalents and restricted cash   (510,038)   278,215 
           
Cash and restricted cash, beginning of year   787,920    732,534 
Cash and restricted cash, end of period  $277,882   $1,010,749 
           
Supplemental Disclosure of Cash Flow Information:          
Cash paid during the period for:          
Interest  $573,529   $1,102,781 
Income taxes  $-   $147,728 
           
Supplemental Disclosure of Noncash Investing and Financing Activities:          
Accounts payable converted to loan payable upon settlement  $-   $3,770,824 
Issuance of common stock for loan financing  $117,648   $- 

 

 

 

6